#1 Clinical Trials Search in Europe

Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

3 1 1

What is this study about?

The study focuses on children aged 2 to under 18 who have Primary IgAN, a rare kidney condition in which a protein called immunoglobulin A builds up in the kidneys and can cause blood and protein to appear in the urine. The medication being tested is a tablet containing atrasentan (also known by the code name EXV811), which is taken by mouth. The purpose of the study is to determine whether this drug can reduce the amount of protein that leaks into the urine.

Participants will receive one tablet each day for about nine months. Throughout the study they will visit the clinic regularly, where health care staff will collect a urine sample, usually the first morning urine, and perform a simple test that compares the protein level to a normal waste product to see how much protein is present. Blood samples will also be taken to understand how the body absorbs and clears the medication. Doctors will monitor safety by checking for any side effects, routine lab results, and vital signs during the visits.

1 baseline visit

you will attend an initial visit where the study team will confirm eligibility and collect baseline information.

a first‑morning urine sample will be taken to measure the urinary protein to creatinine ratio (UPCR), which reflects the amount of protein in the urine.

blood tests and other routine safety assessments will also be performed.

2 start of study medication

after baseline assessments, you will begin taking the investigational drug, atrasentan (also called EXV811).

the medication is a film‑coated tablet to be taken by mouth.

the prescribed dose is 0.75 mg taken once each day.

3 daily medication intake

you will continue to take the 0.75 mg tablet every day for the duration of the study, which lasts up to 36 weeks.

the tablet should be swallowed with water and taken at roughly the same time each day.

4 regular monitoring visits

throughout the study, you will return for scheduled visits, typically every 4 weeks, to allow the study team to check your safety and how the medication is working.

at each visit a first‑morning urine sample will be collected to measure UPCR, and blood tests will be repeated to monitor kidney function and other safety parameters.

any side effects you experience will be recorded and evaluated.

5 week 36 final assessment

at week 36, a final set of assessments will be performed, including a first‑morning urine collection to determine the change in proteinuria compared with baseline.

blood tests and a complete safety review will also be completed to assess any lasting effects of the medication.

6 study completion

after the final assessments, the study medication will be stopped and you will receive a summary of the study findings related to your participation.

your regular medical care will continue as directed by your own healthcare provider.

Who Can Join the Study?

  • You must be at least 2 years old but younger than 18 years on the first day of the study.
  • Your kidney function, measured by eGFR (a test that estimates how well the kidneys filter blood), must be 30 or higher using a special calculation called the modified Schwartz formula, checked at screening and again before treatment starts.
  • You need to have a kidney tissue sample (biopsy) that shows primary IgA nephropathy, taken within the past 3 years, and the sample must show less than 50 % damage called tubulointerstitial fibrosis and less than 25 % of a finding called crescents.
  • You must have significant protein in your urine, measured as a urinary protein to creatinine ratio (UPCR) of 1 gram per gram or more, taken from a first‑morning urine sample (or a spot sample in special cases) at screening and on two earlier visits, even though you have been taking the highest dose of an ACE inhibitor or ARB that you can tolerate for at least 120 days.
  • You must be on stable supportive care, meaning you have been taking a steady dose of an ACE inhibitor or ARB at the maximum amount allowed for your weight (or the highest dose you can tolerate) for at least 120 days before the study drug starts. If you also take diuretics (medicines that help you urinate more), other blood‑pressure medicines, SGLT2 inhibitors (a type of diabetes medicine that can protect the kidneys), or GLP‑1 agonists (another diabetes medicine), those doses must also have been stable for at least 120 days.
  • Your body weight must be at least 10 kilograms (about 22 pounds) when you are screened, and this weight must be confirmed on the first day of treatment.

Who Cannot Join the Study?

  • If you have any form of secondary IgA nephropathy (IgAN) that is linked to other illnesses such as liver scarring (cirrhosis), gluten intolerance (celiac disease), HIV infection, herpes infection, skin rash (dermatitis herpetiformis), a type of arthritis without rheumatoid factor (seronegative arthritis), certain cancers (small‑cell carcinoma, lymphoma), widespread tuberculosis, a lung condition called bronchiolitis obliterans, inflammatory bowel disease, or a genetic fever disorder (familial Mediterranean fever), you cannot join the study.
  • If on the first day of the trial your body weight is lower than the minimum weight allowed for the group you were screened for, and that lower‑weight group is not currently enrolling, you are excluded.
  • If you have a known history of heart problems that you were born with (congenital heart disease), heart failure, or significant fluid buildup such as fluid in the lungs (pulmonary edema), swelling in the legs or arms (peripheral edema), fluid around the lungs (pleural effusion), or fluid in the abdomen (ascites), you cannot participate.
  • If you are currently taking any homeopathic or herbal medicines for IgAN, such as Tripterygium wilfordii (Lei Gong Teng), Caulis sinomenii, or Sinomenium acutum, you are excluded.
  • If your blood pressure is higher than the age‑specific limits (for ages 12‑150/95 mmHg; ages 6‑140/90 mmHg; ages 2‑120/80 mmHg) based on three measurements at screening, or if you have very low blood pressure (hypotension), you cannot join.
  • If you have taken strong immune‑suppressing medicines within the past few months, such as cyclophosphamide, rituximab, infliximab, canakinumab, mycophenolate (MMF or MPS), calcineurin inhibitors, complement inhibitors, oral budesonide, high‑dose steroids (≥0.5 mg/kg/day or >7.5 mg prednisone in one day) within 120 days (or 180 days for rituximab), or endothelin receptor blockers (including sparsentan) within 120 days before the first study drug, you are excluded.
  • If you have major other health problems, such as advanced heart disease (e.g., severe heart failure classified as NYHA class III for ages 6‑<18 or Ross class III for ages 2‑<6), serious lung disease (severe pulmonary disease classified as WHO class III for age 17 or PVRI class III for ages 2‑<17), or active liver disease (like hepatitis) that the doctor thinks would make participation unsafe, you cannot take part.
  • If you have been diagnosed with IgA vasculitis (also called Henoch‑Schönlein purpura), which causes a typical raised rash (palpable purpura) and may include joint pain or belly pain, you are excluded.
  • If you have a significant blockage in the urinary system or any trouble urinating that was found at screening and confirmed at the start of the study, you cannot join.
  • If you have a recent episode of acute kidney injury (AKI) as defined by standard criteria within four weeks before screening, you are excluded.
  • If your kidney function has dropped quickly, defined as a 50 % decline in estimated glomerular filtration rate (eGFR) within three months before screening or during the screening period (a condition called rapidly progressive glomerulonephritis), you cannot participate.
  • If the doctor judges that you have nephrotic syndrome (a kidney condition causing very high protein loss in urine), you are excluded.
  • If a blood test shows a brain‑type natriuretic peptide (BNP) level higher than 200 pg/mL at screening, indicating possible heart stress, you cannot join.
  • If your hemoglobin level is below 9 g/dL (a sign of anemia) at screening or you received a blood transfusion for anemia within the past three months, you are excluded.
  • If your platelet count is less than 80,000 per microliter at screening (a low number of cells that help blood clot), you cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Lyon Sud Pierre Benite France
Hopital Beaujon Clichy France
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Universitario Puerta Del Mar Cadiz Spain
Hrouwbpa Vxjd dldhcdzh Barcelona Spain
Fcyobaslw Pbju Lm Ijqoyddlbaibl Bizhivctz Dee Hztdrvof Ukbcumokdczgb Lb Pnn Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
02.11.2026
Spain Spain
Not yet recruiting
02.11.2026

Trial locations

Investigated Drugs:

atrasentan is an oral tablet being tested in this study. It works by blocking a hormone pathway that can cause damage to the kidneys. The goal of taking this medication is to lower the amount of protein that leaks into the urine (proteinuria) in children who have primary IgA nephropathy. The trial will look at how well the drug works, how it is processed in the body, and whether it is safe for young patients. This medicine has orphan‑drug status, meaning it is intended for a rare condition.

Investigated Diseases:

Primary IgA nephropathy – It is a kidney disorder in which an antibody called IgA accumulates in the tiny filtering units of the kidneys. The deposits cause inflammation and make the filters leak protein into the urine. As the inflammation continues, kidney function can gradually decline and more protein may appear in the urine. The disease usually begins slowly and can progress at varying speeds in different individuals.

Trial ID:
2025-522824-29-00
Protocol code:
CEXV811B12301
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger’s Disease) to Reduce Protein in Urine

    Recruiting

    3 1
    Austria Czechia France Germany Hungary Italy +6